Compare CAC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAC | KALV |
|---|---|---|
| Founded | 1875 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.5M | 551.2M |
| IPO Year | 1997 | N/A |
| Metric | CAC | KALV |
|---|---|---|
| Price | $43.09 | $16.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $47.33 | $26.43 |
| AVG Volume (30 Days) | 64.9K | ★ 1.8M |
| Earning Date | 01-27-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | ★ 9.13 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $215,172,000.00 | $1,426,000.00 |
| Revenue This Year | $44.50 | N/A |
| Revenue Next Year | $7.03 | $204.16 |
| P/E Ratio | $12.35 | ★ N/A |
| Revenue Growth | ★ 27.50 | N/A |
| 52 Week Low | $34.53 | $7.30 |
| 52 Week High | $47.55 | $17.28 |
| Indicator | CAC | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 69.15 | 67.20 |
| Support Level | $41.38 | $13.28 |
| Resistance Level | $41.60 | $16.80 |
| Average True Range (ATR) | 1.16 | 1.09 |
| MACD | 0.29 | 0.28 |
| Stochastic Oscillator | 93.26 | 79.32 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.